NOW APPROVED

Introducing VILTEPSO for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping. Accelerated approval is based on an increase in dystrophin. There is an ongoing study to confirm the clinical benefit of VILTEPSO.

If you are a healthcare provider who treats patients with DMD

Learn More >

If you are a PATIENT or a Caregiver of a child with DMD

Discover Viltepso >

Comprehensive care coordination and support

At NS Support, we are dedicated to being a committed partner to the families coping with Duchenne muscular dystrophy (DMD). We stand ready to provide optimal access support and resources—every step of the way—for patients, their caregivers, and healthcare professionals.

Learn more about ns support >
Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

For more information about VILTEPSO, see full Prescribing Information.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.

For more information about VILTEPSO, see full Prescribing Information.